TÜBINGEN, Germany / BOSTON, MA, Nov. 7, 2018 – CureVac AG, a fully integrated biopharmaceutical company pioneering the field of mRNA-based drugs, today announced it will present preliminary data from its Phase I dose-escalation clinical trial with the RNA-based cancer therapy, CV8102, in patients with advanced solid tumors. These data will be presented as a poster presentation at the 2018 Society of Immunotherapy of Cancer (SITC) Annual Meeting in Washington, DC, Nov. 7-11, 2018.
Poster Presentation Details
Title: Phase I dose-escalation and expansion study of intratumoral CV8102, a RNA-based TLR- and RIG-1 agonist with or without anti-PD1 antibodies in patients with advanced solid tumors
Session: Friday, November 9, 2018, 12:45 PM-2:15 PM and 6:30 PM-8:00pm EST
Poster Number: P337; Location: Hall E, Walter E. Washington Convention Center
About CV8102 and the Phase I Clinical Trial
CV8102, a TLR7/8/RIG-1 agonist based on noncoding single stranded RNA, is designed to modulate the tumor microenvironment after intratumoral injection and to induce a systemic immune response to control injected as well as non-injected distant lesions.
The CV8102 phase I, open-label, dose escalation and expansion study is enrolling patients with advanced melanoma, cutaneous squamous cell carcinoma, squamous cell carcinoma of head and neck, or adenoidcystic carcinoma and superficially injectable tumor lesions.
The trial is currently enrolling patients at multiple clinical sites in Germany. The trial tests escalating doses of single agent CV8102 and CV8102 in combination with licensed anti-PD-1 antibodies.
The primary objective of the study is to assess safety and tolerability. Secondary objectives are to assess clinical efficacy and changes in various immune parameters in blood and tumor tissue.